ProSharesInverse EquityBIS · Nasdaq

ProShares UltraShort Nasdaq Biotechnology (BIS)

Compare categoryCompare Leveraged & Inverse ETFs Compare with others

Price: $10.54; —12 Nov 2026
Assets: $1.7M; Total net assets
Expense ratio: 0.95%; Category 0.00%
Yield: 5.90%; Trailing distributions

1Y return: -46.2%-17.2%; Category -29.0%
3Y CAGR: -38.4%-2.6%; Category -35.8%
5Y CAGR: -21.2%+2.5%; Category -23.7%

$10.54—12 Nov 2026

Fund

Assets: $1.7M
Expense: 0.95%
Categ. exp: 0.00%
Yield: 5.90%

ReturnFundCateg.

1Y-46.2%-29.0%

3Y-38.4%-35.8%

5Y-21.2%-23.7%

Launch-33.1%—

Loading NAV history…

ProShares UltraShort Nasdaq Biotechnology

Calendar-year returns

Fund only: no comparison series covers this fund's history.

Risk statistics

Five years of daily closes. Risk-free rate 4% a year.

Standard deviation: —
Maximum drawdown: —
Sharpe ratio: —
Sortino ratio: —
Beta: —
Alpha: —
R²: —
Information ratio: —
Upside capture: —
Downside capture: —
Tracking error: —

Trailing returns compared with benchmark
Period	1M	3M	6M	YTD	1Y	3YCAGR	5YCAGR	10YCAGR	LaunchCAGR
ETF	-14.5%	-15.1%	-35.4%	-42.8%	-46.2%	-38.4%	-21.2%	-25.8%	-33.1%
Inverse Equity average	11.5%	8.2%	-9.1%	-31.0%	-29.0%	-35.8%	-23.7%	-29.3%	-37.1%
Difference	-25.9%	-23.3%	-26.3%	-11.8%	-17.2%	-2.6%	+2.5%	+3.5%	+4.0%

Holdings

Allocation as last published by the fund.

Asset mix

What the fund is invested in.

Cash199.9%
Other100.0%

ETF details

Issuer: ProShares
Category: Equity · Inverse Equity
Ticker: BIS
Exchange: Nasdaq
Inception: 6 Apr 2010 (16.6 years)
Structure: Exchange Traded Fund
Expense ratio: 0.95% (category 0.00%)
Holdings turnover: 0%
Distribution yield: 5.90%
Beta, 3 years: -1.07
Total net assets: $1.7M

Prices and returns as of 12 Nov 2026; total return with distributions reinvested, before brokerage and taxes. Not investment advice.

Other inverse equity ETFs

Other ETFs in the Inverse Equity category.

Compare Leveraged & Inverse ETFs